X

Trial Profile

BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) EUropean Angiography Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ridaforolimus (Primary) ; Zotarolimus
Indications Coronary artery disease
Focus Registrational; Therapeutic Use
Acronyms NIREUS
Sponsors Medinol

Most Recent Events

21 Dec 2016 According to a Medinol media release, results from this trial presented at the opening Late Breaking Trial session of the 28th annual Transcatheter Cardiovascular Therapeutics (TCT2016) scientific symposium.
17 May 2016 Results (n=302) published in a Medinol media release.
17 May 2016 According to a Medinol media release, results of this trial were presented at the EuroPCR 2016 conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com